Comments on: Academic Funds & Conflicts: Eric Campbell Explains http://www.pharmalot.com/2008/07/academic-funds-conflicts-eric-campbell-explains/ News, Comment and Conversation Fri, 10 Feb 2012 20:53:43 +0000 http://wordpress.org/?v=2.6.2 By: Ed Silverman http://www.pharmalot.com/2008/07/academic-funds-conflicts-eric-campbell-explains/#comment-365328 Ed Silverman Thu, 03 Jul 2008 02:27:47 +0000 http://www.pharmalot.com/?p=14411#comment-365328 Hi CMC Guy, Thanks for the kind words, but Campbell deserves them. He was very thoughtful and I enjoyed the discussion, because he can get one thinking. In any event, glad you enjoyed it. Regards ed Hi CMC Guy,

Thanks for the kind words, but Campbell deserves them. He was very thoughtful and I enjoyed the discussion, because he can get one thinking. In any event, glad you enjoyed it.

Regards
ed

]]> By: CMC guy http://www.pharmalot.com/2008/07/academic-funds-conflicts-eric-campbell-explains/#comment-365323 CMC guy Thu, 03 Jul 2008 02:14:02 +0000 http://www.pharmalot.com/?p=14411#comment-365323 Ed and Dr Campbell thank you for capturing/expressing a balanced view on this issue. The last paragraph is particularly important as indeed requires trust and lack of prejudgments. Industry/Academics relationship are not bad outright (and IMO very necessary to progress) although there are potential risks so need awareness. I think pharma industry has sometimes taken unjustified hits for failures/poor acts by academic institutions/individuals because they provided money with expectation that would be handled properly. I don't know if a common form would be practical solution (and seems Bureaucratic) or just setting national standards then each institution can implement what is needed/works for them. Ed and Dr Campbell thank you for capturing/expressing a balanced view on this issue. The last paragraph is particularly important as indeed requires trust and lack of prejudgments. Industry/Academics relationship are not bad outright (and IMO very necessary to progress) although there are potential risks so need awareness.

I think pharma industry has sometimes taken unjustified hits for failures/poor acts by academic institutions/individuals because they provided money with expectation that would be handled properly. I don’t know if a common form would be practical solution (and seems Bureaucratic) or just setting national standards then each institution can implement what is needed/works for them.

]]>